What is a CDMO & How are They Revolutionizing the Pharmaceutical Industry?
Unlike a CMO (Contract Manufacturing Organization), which focuses solely on large-scale production, a CDMO supports clients from early-stage development through to commercial manufacturing, helping reduce costs and maintain quality control throughout the entire manufacturing process. These drug development projects can range from clinical trial services for small molecule compounds to large-scale GMP manufacturing of biologics, monoclonal antibody therapies, and even gene therapy and viral vector production.
Challenges CDMOs Help Solve
Partnering with a CDMO can help any pharmaceutical company or biotech firm in many ways. A full-service contract development and manufacturing organization has access to well-qualified:
- Chemists and engineers
- Development specialists
- Experienced researchers
- Staff to manage the manufacturing process from start to finish
This allows clients to outsource complex processes and avoid the significant resources, commitment, and costs associated with drug development, pharmaceutical manufacturing, and distribution. Here are some of the top challenges CDMO services can address:
Problem: Cost Management
Solution: Developing and manufacturing in the pharmaceutical industry can be expensive. CDMOs help their clients manage costs by leveraging their extensive experience and economies of scale to optimize the manufacturing process and reduce waste, whether working with oral dosage forms, nasal spray formulations, or pre-filled syringes.
Problem: Capacity Constraints
Solution: Many biotech companies and mid-sized pharmaceutical firms lack the internal capacity to manufacture new products at scale. A global CDMO can provide the manufacturing facility resources and flexibility needed to meet demand across clinical phases and commercial production.
Problem: Regulatory Compliance
Solution: The pharmaceutical industry is heavily regulated, and companies must comply with a wide range of regulatory requirements related to quality, safety, and efficacy. CDMOs provide regulatory expertise and quality control support, helping clients satisfy regulatory authorities and maintain the highest standards throughout production.
Problem: Technology & Innovation
Solution: The pharmaceutical industry is constantly evolving, and companies must stay current with advanced technologies and process improvements. CDMOs provide access to:
- Innovative manufacturing equipment
- Validated analytical methods
- Scientific expertise in route scouting for new drug substances
- Visual inspection systems for finished products
Problem: Speed to Market
Solution: Developing pharmaceutical products can be a lengthy process. CDMOs help their clients accelerate time to market by applying their experience and equipment to optimize the manufacturing process and shorten development, manufacturing, and approval timelines.
Breaking Down a CDMO's Services
A CDMO can play a variety of distinct roles in the pharmaceutical industry. Each offering is aimed at getting a drug product to market in a timely manner and at a lower cost, whether that product is a small molecule, a biologic, or a life-changing therapy for underserved patient populations.
Drug Development & Drug Discovery
The drug development timeline can vary widely—around 6 to 10 years—depending on the drug candidate, project scope, and regulatory requirements. CDMOs with deep scientific expertise and technical knowledge can often expedite certain stages. The typical progression includes:
- Research & Safety Profiling of the target drug candidate
- Formulation development—optimizing solubility, stability, and bioavailability for safe delivery
- Analytical testing using validated analytical methods to confirm drug product quality and consistency
- Clinical trials testing safety and efficacy across multiple clinical phases
- Commercial manufacturing and scaling for distribution to improve patients’ lives worldwide
CDMO Manufacturing Services
Like the development phase, manufacturing services represent a lengthy process that depends on the complexity of the drug substance, manufacturing facility capacity, and the requirements of regulatory authorities. CDMO manufacturing can involve:
- Planning and raw materials sourcing
- GMP manufacturing
- Quality control and analytical testing
- Packaging and labeling
- Distribution and clinical supply management
Many CDMOs now offer pharma solutions that span the full supply chain—from early-stage development through commercial production.
Packaging in CDMO Processes
The packaging process is an important part of a CDMO’s offerings, as it protects the final drug product and supports regulatory compliance. With the right equipment, tracking, materials, and labeling solutions in place, a CDMO can optimize pharmaceutical or biopharmaceutical packaging to deliver greater efficiency.
Primary Packaging: Identifying the primary packaging is a first step. Options can include:
- Bottles and vials
- Syringes and pre-filled syringes
- Blister packs
All primary packaging must be compatible with the drug product and meet regulatory requirements.
Labeling: After the primary package and equipment are identified, labeling must be integrated into the packaging process. Labels can include:
- Drug name, indications, and usage
- Dosage and administration
- Contraindications, warnings, and precautions
- Drug interactions
- Storage, handling, and expiration date
- Manufacturer information and more depending on the specific drug and intended use
If necessary, the drug product may also be placed into secondary packaging such as cartons, boxes, pouches, and trays, with additional labeling or instructions added as required. Once packaged and labeled, the drug product is stored under appropriate conditions and distributed in compliance with regulatory authorities.
Distribution
A CDMO can also play a significant role in the distribution of pharmaceutical products. Responsibilities can include:
- Storage and inventory management
- Order fulfillment
- Quality control and regulatory compliance
- Customer support
Who Benefits from a CDMO Partnership?
Partnering with a CDMO partner can prove beneficial for a wide range of organizations in the pharmaceutical industry and healthcare space:
Startups and small biotech companies: With high costs and complex manufacturing processes, these organizations may not have the resources to develop and manufacture products in-house. Working with a CDMO provides access to scientific expertise, manufacturing facility capacity, navigation through regulatory requirements, and faster speed to market.
Established pharmaceutical companies: Even large pharma firms can benefit from CDMO services, especially for new or niche products, including monoclonal antibody treatments, gene therapy programs, or viral vector production, which require specialized manufacturing processes. Outsourcing parts of the drug development process can reduce costs and improve efficiency.
Contract research organizations (CROs): CROs provide clinical trial services to pharmaceutical and biotech companies. By partnering with a CDMO, CROs can offer a broader range of services, including manufacturing and analytical testing, helping them differentiate in a competitive market.
Generic drug manufacturers: Generic drug manufacturers can benefit from working with CDMOs to develop and manufacture their products, reducing costs and increasing their competitiveness—especially for oral dosage forms and other high-volume drug products.
The Importance of Scalability
CDMOs take on projects that vary in scale—from small clinical trial batches and clinical supply needs to large-scale commercial manufacturing. The ability to scale operations across the full lifecycle is what separates a capable CDMO from a limited one.
- Equipment & Facilities: A manufacturing facility must accommodate changes in production volume, with flexible equipment that adjusts from early-stage development runs to full-scale commercial output.
- Supply Chain Management: A reliable supply chain supports any level of pharmaceutical manufacturing—from sourcing raw materials and intermediates to maintaining supplier partnerships that deliver at the required quantities and quality.
- Quality Control: Quality control measures must be in place at all stages of the manufacturing process. As production volume grows, meeting the highest standards becomes more demanding, making disciplined quality systems even more important.
Future Trends for CDMOs
The global CDMO market is on a strong growth trajectory—projected to reach approximately $580 billion by 2034 Fortune Business Insights, driven by increasing outsourcing demand and the rising complexity of innovative therapeutics. Capacity bottlenecks, particularly in complex injectable dosage forms such as pre-filled syringes, are expected to intensify through 2026 as more biologics enter the market.
Several trends are shaping the future of CDMO services:
- AI and machine learning are being integrated to improve predictive analytical development and process optimization, shortening drug development timelines
- Biologics, personalized medicine, and gene therapy are driving CDMOs to expand their capabilities across new therapeutic modalities
- Sustainability is becoming a priority, leading to greener manufacturing practices and eco-friendly packaging
- Reshoring and supply chain diversification are accelerating, particularly for manufacturing services in North America and allied regions
These trends will directly affect packaging, driving demand for innovative, compliant packaging solutions that maintain the integrity of sensitive biologic drugs.
Packaging Solutions to Scale Alongside Your Development
Medical Packaging Inc., LLC (MPI) serves as a one-stop shop for a variety of healthcare organizations, including CDMOs, by offering the packaging equipment, materials, software, and support needed to optimize drug packaging while maintaining the ability to scale as your production volume grows.
With complete medication packaging solutions, MPI systems promote the highest standards of efficiency, compliance, and traceability throughout the manufacturing and drug administration process.
FD-Pharma® Unit Dose Packaging System: With a built-in printing and pumping system, MPI’s FD-Pharma® is an automated, barcoding packaging solution for unit dose oral liquid. Offering the ability to scale from low production to full commercial manufacturing modes, the FD-Pharma® is appropriate for CDMOs serving a wide range of clients—from those in clinical trial phases to those with larger manufacturing needs.
Our full line of products provides a viable solution for companies to scale their medical packaging process using trusted and federally compliant systems:
Contact MPI Today
For more information about our medication packaging systems, materials, technical questions, quality assurance, or assistance with your current system, contact our customer success team.
Contact MPI Today for Personal Assistance
MPI’s Drug Master File provides speed-to-market regulatory and technical support related to our packaging components for medical and pharmaceutical market clients